Immix Biopharma (IMMX) Amortizatization of Intangibles (2021 - 2026)
Immix Biopharma (IMMX) posted Amortizatization of Intangibles of $39189.0 for Q1 2026, up 1.74% sequentially from $38517.0 in Q4 2025, and up 86.37% YoY from $21027.0 in Q1 2025.
Immix Biopharma (IMMX) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Immix Biopharma has reported Amortizatization of Intangibles for 4 years, with the latest figure at $39189.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 86.37% year-over-year to $39189.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136916.0 (up 65.69% YoY) and the FY2025 annual result came in at $118754.0, up 44.04% from the prior year.
- Amortizatization of Intangibles improved to $39189.0 in Q1 2026 per IMMX's latest filing, from $38517.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $39189.0 in Q1 2026 and troughed at $20416.0 in Q2 2024.
- A 3-year average of $26710.0 and a median of $21027.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2025 and 2026: Amortizatization of Intangibles increased 0.9% in 2025, then jumped 86.37% in 2026.
- Over 3 years, Amortizatization of Intangibles stood at $20734.0 in 2024, then surged by 85.77% to $38517.0 in 2025, then advanced by 1.74% to $39189.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $39189.0, $38517.0, and $37869.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.33 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 678,000.00 |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 39,891.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39,891.00 |
| Jun 30, 2026 | 39,891.00 |
| Mar 31, 2026 | 39,189.00 |
| Mar 31, 2026 | 39,189.00 |
| Dec 31, 2025 | 38,517.00 |
| Dec 31, 2025 | 38,517.00 |
| Sep 30, 2025 | 37,869.00 |
| Sep 30, 2025 | 37,869.00 |
| Jun 30, 2025 | 21,341.00 |
| Jun 30, 2025 | 21,341.00 |
| Mar 31, 2025 | 21,027.00 |
| Mar 31, 2025 | 21,027.00 |
| Dec 31, 2024 | 20,734.00 |
| Dec 31, 2024 | 20,734.00 |
| Sep 30, 2024 | 20,457.00 |
| Sep 30, 2024 | 20,457.00 |
| Jun 30, 2024 | 20,416.00 |
| Jun 30, 2024 | 20,416.00 |
| Mar 31, 2024 | 20,840.00 |
| Mar 31, 2024 | 20,840.00 |